VYNE Therapeutics (VYNE)

• Market cap: $8.97M
• 1 day: -2.41%
• 5 days: -3.35%
• 1 month: 7.08%
• 3 months: -75.7%
• 6 months: -75.53%
• Year to date: -89.42%
• 1 year: -87.6%
• 5 years: -99.7%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Employees: 13